Gilead Sciences , Inc. (NASDAQ:GILD) is scheduled to be announcing its Q114 earnings results on Tuesday, April 22nd. Analysts expect the company to announce earnings of $0.85 per share and revenue of $3.80 billion for the quarter.Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $69.37 moved to $70.64 on last trade day and at the end of the day closed at $70.00. Company price to sales ratio in past twelve months was calculated as 9.61 and price to cash ratio as 50.50. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 6.90%.
Biogen Idec Inc. (NASDAQ:BIIB) has priced its newly approved hemophilia B drug Alprolix at a level that puts it at cost parity with drugs already on the US market to control and prevent bleeding, a representative of the Cambridge drug maker said Friday. Biogen Idec Inc (NASDAQ:BIIB) shares fell -0.32% in last trading session and ended the day on $290.54. BIIB return on equity ratio is recorded as 23.30% and its return on assets is 16.90%. Biogen Idec Inc (NASDAQ:BIIB) yearly performance is 46.25%.
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss first quarter 2014 financial and operational results. Celgene Corporation (NASDAQ:CELG) shares moved down -0.25% in last trading session and was closed at $141.51 while trading in range of $140.29 – $144.07 – Celgene Corporation (NASDAQ:CELG) year to date (YTD) performance is -16.25%.
AbbVie Inc. (NYSE:ABBV) provided an update on its experimental cancer drug which has been moved into a pivotal study (n=900). AbbVie’s PARP inhibitor, veliparib’s safety and efficacy will be evaluated in a randomized, placebo-controlled, double-blind, multicenter phase III study which will be conducted in previously untreated patients suffering from locally advanced or metastatic squamous non-small cell lung cancer. AbbVie Inc (NYSE:ABBV) weekly performance is 3.45%. On last trading day company shares ended up $48.55. AbbVie Inc (NYSE:ABBV) distance from 50-day simple moving average (SMA50) is -3.70%. Analysts mean target price for the company is $53.59.
Leave a Reply